Theriva Biologics (TOVX) executive compensation, 2025 proxy

Steven Shallcross, Chief Executive Officer and Chief Financial Officer, was paid $876,313 in 2024, down 31% from $1.3M the year before.

Open TOVX in Gloom →
Theriva Biologics' chart, financials and news, free in your browser.Open TOVX in Gloom →
Filed
July 9, 2025
Annual meeting
August 29, 2025
Pay year
2024
Named executives
1
CEO total pay
$876,313-31% vs prior year
Prior say-on-pay support
97%of votes cast
Salary share
67%Of target compensation
Variable compensation
33%Of target compensation
2023 total compensation
$1,271,913Prior fiscal year
2025 option grant
190,000 sharesGranted May 1, 2025

How Shallcross was paid

$876,313 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary74%Bonus23%All other compensation4%

Named executive officers

ExecutiveTotal
Steven ShallcrossChief Executive Officer and Chief Financial Officer$876,313

What changed and why

  • $876K$876,313 CEO total compensation in 2024, down from $1,271,913 in 2023.
  • $645K$644,963 CEO salary increased from $614,250 in 2023.
  • $200K$200,000 annual cash bonus was paid for 2024 performance.
  • No equity awards were granted to the CEO during 2024.
  • 67%67% of target compensation was salary and 33% was performance-based variable compensation.
  • 190,000 stock options were granted to the CEO on May 1, 2025 for 2024 services.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.